PAREXEL INTERNATIONAL WELCOMES DR. MATTHEW THATCHER TO REGULATORY CONSULTING GROUP, EUROPE
BOSTON, MA, December 9, 2003 — PAREXEL International Corporation (Nasdaq: PRXL), one of the world’s largest biopharmaceutical outsourcing companies, today announced the addition of Matthew J. Thatcher, MD, as a Principal Consultant in the Worldwide Regulatory Affairs group. Reporting to Carrol Marcus in PAREXEL’s Uxbridge, UK office, Dr. Thatcher joins the Company from the UK Medicines and Healthcare Products Regulatory Agency (MHRA, formally MCA.) He complements PAREXEL’s existing global team of Principal and Senior Consultants, including several former senior regulatory authority assessors who advise biopharmaceutical clients on a wide range of multinational and local regulatory matters.
Bringing over twenty-five years of scientific, regulatory and management experience to PAREXEL‘s Worldwide Regulatory Affairs group, Dr. Thatcher was a Senior Medical Officer at the MHRA for over 12 years. During his time at the MHRA, he worked in the New Chemical Entities, Pharmacovigilance, Biologicals and Variations Units, and was responsible for clinical assessments for the UK’s Committee on Safety of Medicines and Medicines Commission and for the EMEA’s Committee for Proprietary Medicinal Products. Dr. Thatcher was previously a Regulatory Consultant to the pharmaceutical industry and also worked in the medical device industry. He has broad clinical experience in the UK, including surgical specialities, radiology and general practice. Dr. Thatcher obtained his Medical Qualification from London University. He received his Postgraduate Surgical Degree from the Royal College of Surgeons, London and Edinburgh and his Diplomas in Diagnostic Radiology and Obstetrics and Gynaecology from the Royal Colleges of Radiologists and Obstetricians and Gynaecologists, respectively.
“We are delighted and proud to welcome Dr. Thatcher to our regulatory team,” said Alberto Grignolo, PhD, President, Worldwide Regulatory Affairs. “His extensive knowledge of regulatory requirements and the biopharmaceutical industry will be a valuable asset and help us to maintain a leading position in Regulatory Consulting.”
PAREXEL is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), Clinical Trial Management Systems (CTMS), electronic diary and investigator database solutions. Perceptive also offers advanced medical diagnostics services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. PAREXEL’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 57 locations throughout 36 countries around the world, and has 5,105 employees.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective owners and are hereby acknowledged.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", “estimates”, “projects” and similar expressions are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company’s Form 10-Q for the quarter ended September 30, 2003 as filed with the Securities and Exchange Commission on November 12, 2003, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update forward-looking statements in the future. The forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.